Wait a year or two and spring the mix on a biotech-crazed investment world. You don't invest in the horse, you invest in the jockey. He's only 32 and speaks in the precise, reassuring cadence of a man twice his age. The only difference is the energy level. There's a distinctly youthful turbocharge behind his conversational rifts.
Most people consider the management to be the most important thing.
Second would be the technology and third would be financing. This is someone who's done things that are for real and has been successful doing it. Case precisely in point, of course, is Kuo himself. He combined a Wharton MBA with a Penn MD to win entry into the biotech venture capital business. What the situation usually requires is an older, very experienced person from the pharmaceutical industry.